Literature DB >> 10580751

Levothyroxine-induced liver dysfunction in a primary hypothyroid patient.

M Ohmori1, K Harada, S Tsuruoka, K Sugimoto, E Kobayashi, A Fujimura.   

Abstract

Here we report a case of levothyroxine-induced liver dysfunction. T4 (levothyroxine) has been more commonly used for the treatment of hypothyroidism than T3 active hormone (triiodothyronine), because with the former drug a stabler plasma concentration is obtained after oral administration. Although there are few reports on levothyroxine-induced liver dysfunction, we treated a primary hypothyroid patient with high serum aminotransferase after administration of levothyroxine. Liver dysfunction was improved after cessation of the drug administration. Antibody to T4 was found in the serum of the patient after this event. From clinical course and laboratory data of the patient, the episode of liver damage was considered to be induced by levothyroxine. We then administrated triiodothyronine, and it did not induce liver dysfunction. Changing levothyroxine to triiodothyronine resulted in a successful clinical course in this case, as re-administration of the doubtful drug is strictly limited.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580751     DOI: 10.1507/endocrj.46.579

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  3 in total

Review 1.  Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

Authors:  Peter Laurberg; Stig Andersen; Inge Bülow Pedersen; Allan Carlé
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Levothyroxine-induced liver injury followed by complete recovery upon cessation of the drug: a case report.

Authors:  Abbas F Hlaihel; Mudher Z H Al-Khairalla
Journal:  J Med Case Rep       Date:  2019-10-18

3.  Liver Stiffness in Obese Hypothyroid Patients Taking Levothyroxine.

Authors:  Roberta Pujia; Elisa Mazza; Tiziana Montalcini; Franco Arturi; Antonio Brunetti; Antonio Aversa; Stefano Romeo; Maria Perticone; Angela Sciacqua; Arturo Pujia
Journal:  Medicina (Kaunas)       Date:  2022-07-18       Impact factor: 2.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.